REBIOPSY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AS THE BASIS OF INDIVIDUALIZED TREATMENT

ORIGINAL ARTICLES. A. PROTOCOLS OF CLINICAL RESEARCH

https://doi.org/10.37469/0507-3758-2017-63-3-440-444

Published 01.03.2017

Konstantin Laktionov⁺⁻
Andrey Zaretskiy⁺⁻
Denis Yudin⁺⁻
Dmitriy Shagin⁺⁻
Valeriy Breder⁺⁻

Konstantin Laktionov

N.N. Blokhin Russian Cancer Research Center

Andrey Zaretskiy

N.I.Pirogov Russian National Research Medical University, Evrogen Lab LLC

Denis Yudin

N.N. Blokhin Russian Cancer Research Center

Dmitriy Shagin

N.I.Pirogov Russian National Research Medical University

Valeriy Breder

N.N. Blokhin Russian Cancer Research Center

##article.numberofdownloads## 105

##article.numberofviews## 346

PDF (Русский)

Keywords

NON-SMALL CELL LUNG CANCER
PROGRESSION
REPEATED TUMOR BIOPSY (REBIOPSY)
THORACOSCOPY
MOLECULAR TESTING
MUTATIONS
TARGETED THERAPY
IMMUNOTHERAPY
PERSONALIZED TREATMENT

How to Cite

Laktionov, K., Zaretskiy, A., Yudin, D., Shagin, D., & Breder, V. (2017). REBIOPSY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER AS THE BASIS OF INDIVIDUALIZED TREATMENT. Voprosy Onkologii, 63(3), 440–444. https://doi.org/10.37469/0507-3758-2017-63-3-440-444

Abstract

We have conducted a pilot study of repeated tumor biopsy followed by molecular testing in order to facilitate treatment correction in patients with advanced non-small cell lung cancer progressing on their current therapy. Repeated tumor biopsy was showed to be feasible, well tolerated and highly informative. Use of molecular-matched therapy was associated with significant increase in overall survival in this difficult-to-treat group of cancer patients.

https://doi.org/10.37469/0507-3758-2017-63-3-440-444

##article.numberofdownloads## 105

##article.numberofviews## 346

PDF (Русский)

References

Аллахвердиев А. К., Лактионов К. К., Полоцкий Б. Е., Давыдов М. И. Современные возможности видеоторакоскопии в практике торакальной онкологии // Вестник Московского онкологического общества. - 2009. - Т. 5. - № 6-8 (559). - С. 2-4

Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2012 г. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. / Под ред. Давыдова М. И., Аксель Е. М. - М., 2014. - 226 с.

Каприн А. Д., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2015 году. - М., 2016. - 236 с.

Bosc C., Ferretti G. R., Cadranel J. et al. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC // Target Oncol. - 2015. -Vol. 10 (2). - P 247-53. - DOI: 10.1007/s11523-014-0332-y

Du L., Herbst R. S., Morgensztern D. Immunotherapy in lung cancer // Hematol. Oncol. Clin. North Am. -2017. - Vol. 31 (1). - P. 131-141. - 10.1016/j. hoc.2016.08.004. DOI: 10.1016/j.hoc.2016.08.004

IASLC/CAP/AMP Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision 2016 // https://www.iaslc.org/sites/default/files/wysiwyg-assets/5-20160616capiaslcamplungguideline-2016draftrecommendations_ocpfinal.pdf.

Langer C.J., Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer // Cancer Treat. Rev. - 2013. - Vol. 39 (3). - P 252-60. - 10.1016/j. ctrv.2012.05.003. DOI: 10.1016/j.ctrv.2012.05.003

Levy M.A., Lovly C.M., Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm // Genome Res. - 2012. - Vol. 22 (11). - P 2101-2108. - DOI: 10.1101/gr.131128.111

Meador C.B., Micheel C.M., Levy M.A. et al. Beyond histology: translating tumor genotypes into clinically effective targeted therapies // Clin Cancer Res. - 2014. - Vol. 20 (9). - P 2264-2275. - CCR-13-1591. DOI: 10.1158/1078-0432

NCCN Guidelines with Evidence Blocks: Non-Small Cell Lung Cancer Version 3.2017 // http://www.nccn.org/ professionals/physician_gls/pdf/nscl_blocks.pdf.

Pao W., Miller V., Zakowski M. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib // Proc. Natl. Acad. Sci. U S A. -2004. - Vol. 101 (36). - P. 13306-13311.

Sacher A.G., Paweletz C., Dahlberg S.E. et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer // JAMA Oncol. - 2016. - Vol.2 (8). - P. 1014-1022. - DOI: 10.1001/jamaoncol.2016.0173

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Tatyana Borisova, Arif Allakhverdiev, Yuriy Gerasimov, Nadezhda Meshcheryakova, Mikhail Dolgushin, Valeriy Breder, Konstantin Laktionov, Sevil Alieva, Stanislav Ivanov, Sergey Tkachev, Aleksey Nazarenko, S. Loraeva, STEREOTACTIC HYPO-FRACTIONAL RADIOTHERAPY OF PATIENTS WITH LUNG CANCER I-IIA CLINICAL STAGE: THE ROLE OF SUVMAX ASSESSMENT IN 18F-FDG PET/CT FOR MONITORING TREATMENT OUTCOMES , Voprosy onkologii: Vol. 63 No. 4 (2017)
Tatyana Borisova, M. Ardzinba, A. Fedorova, Valeriya Glebovskaya, Oksana Trofimova, Dimitr Marinov, Yelena Reutova, Stanislav Ivanov, Sevil Alieva, Nadezhda Meshcheryakova, Valeriy Breder, Konstantin Laktionov, Sergey Tkachev, Aleksey Nazarenko, N. Marinichenko, HIGH-TECH RADIATION THERAPY WITH LOCAL DOSE ESCALATION IN CHEMO-RADIATION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER. PREDICTORS OF EFFECTIVENESS , Voprosy onkologii: Vol. 64 No. 6 (2018)
Konstantin Laktionov, Yelena Reutova, Natalya Kormosh, Valeriy Breder, A. Gorokhov, LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT , Voprosy onkologii: Vol. 65 No. 3 (2019)
Konstantin Laktionov, Alla Arzumanyan, Larisa Bolotina, Valeriy Breder, Natalya Buevich, A. Danilova, Anna Zinkovskaya, Anna Kornietskaya, M. Kramchaninov, Ye. Kushniruk, Dilorom Latipova, Fedor Moiseenko, Tatyana Nikitina, Mariya Okruzhnova, Sergey Orlov, Rashida Orlova, N. Porfireva, Svetlana Protsenko, Kseniya Sarantseva, Daniil Stroyakovskiy, Yelena Filippova, Tatyana Ionova, EFFICACY OF NIVOLUMAB (NWO) DURING 2+ LINE TREATMENT AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED REFRACTORY NON-SMALL CELL LUNG CANCER: INTERIM RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY , Voprosy onkologii: Vol. 65 No. 1 (2019)
Denis Fedyaev, V. Ignateva, Yelena Derkach, Sergey Zyryanov, Konstantin Laktionov, Tatyana Semiglazova, COMPARATIVE PHARMACOECONOMIC EVALUATION OF THE USE OF AFATINIB AND GEFITINIB IN THERAPY FOR LUNG CANCER , Voprosy onkologii: Vol. 63 No. 1 (2017)
Konstantin Laktionov, Denis Yudin, Yuliya Maevskaya, Lyubov` Vladimirova , Dimitr Marinov, Merab Ardzinba, Amir Abdullaev, Irina Popova, Efficiency integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer and an activating EGFR gene mutation. , Voprosy onkologii: Vol. 67 No. 2 (2021)
Tatyana Borisova, S. Tkachev, S. Ivanov, S. Alieva, O. Trofimova, V. Glebovskaya, Valeriy Breder, K. Laktionov, Dimitr Marinov, A. Abdullaev, RADIATION THERAPY IN MULTIMODAL TREATMENT OF PATIENTS WITH PLEURAL MESOTHELIOMA. LITERATURE REVIEW AND ANALYSIS OF OWN OBSERVATIONS , Voprosy onkologii: Vol. 66 No. 5 (2020)
Valeriy Breder, Boris Dolgushin, Anatoliy Kukushkin, Igor Trofimov, Vladislav Kosyrev, Lyudmila Kostyakova, Eduard Virshke, Konstantin Laktionov, Irina Dzhanyan, M. Pitkevich, TRANSARTERIAL CHEMOEMBOLIZATION(TACE) EFFICACY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA(HCC): CAN SIGNIFICANT PROGNOSTIC FACTORS BE REVEALED? , Voprosy onkologii: Vol. 64 No. 6 (2018)
M. Natrusova, Valeriy Breder, Irina Dzhanyan, Oleg Olisov, Murad Novruzbekov, Yekaterina Moroz, P. Murashova, M. Pitkevich, Konstantin Laktionov, BRAIN METASTASES AFTER LIVER TRANSPLANTATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: THE CHOICE OF THERAPY , Voprosy onkologii: Vol. 65 No. 6 (2019)
Konstantin Laktionov, A. Kazakov, Kseniya Sarantseva, Yelena Reutova, A. Arzumanyan, N. Moskalyuk, THE ROLE OF LIQUID BIOPSY IN THE CHOICE OF TACTICS FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER , Voprosy onkologii: Vol. 66 No. 5 (2020)

1 2 > >>